GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kumar, Krishan ^a,b   Raza, Sania S ^a   Knab, Lawrence M ^a   Chow, Christina R ^a   Kwok, Benjamin ^a   Bentrem, David J ^a,b   Popovic, Relja ^a   Ebine, Kazumi ^a,b   Licht, Jonathan D ^a   Munshi, Hidayatullah G ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(+)-JQ1 COMPOUND; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; AZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; GLI2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MYC PROTEIN; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; TRIAZOLE DERIVATIVE;

APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

APOPTOSIS; AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926376050     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09489     Document Type: Article

References (56)

1. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073, doi:nature09504 (2010).
2. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917, doi:S0092-8674(11)00943-3 (2011).
3. Lockwood, W. W., Zejnullahu, K., Bradner, J. E., Varmus, H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA 109, 19408-19413, doi:1216363109 (2012).
4. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528, doi:nature10334 (2011).
5. Puissant, A. et al. Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discov 3, 308-323, doi:2159-8290. CD-12-0418 (2013).
6. Tang, X. et al. BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis. Mol Pharmacol 83, 283-293, doi:mol. 112. 081661 (2013).
7. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533, doi:nature10509 (2011).
8. Ceribelli, M. et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci USA 111, 11365-11370, doi:10. 1073/pnas. 1411701111 (2014).
9. Liu, S. et al. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther 13, 1194-1205, doi:10. 1158/1535-7163. MCT-13-0341 (2014).
10. Shao, Q. et al. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Cancer Res 74, 7090-7102, doi:10. 1158/0008-5472. CAN-14-0305 (2014).
11. Baratta, M. G. et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci USA 112, 232-237, doi:10. 1073/pnas. 1422165112 (2015).
12. Cheng, Z. et al. Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma. Clin Cancer Res, doi:1078-0432. CCR-12-3066 (2013).
13. Sahai, V. et al. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther, doi:1535-7163. MCT-13-0925 (2014).
14. Pfannkuche, K., Summer, H., Li, O., Hescheler, J., Droge, P. The high mobility group proteinHMGA2: a co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev 5, 224-230, doi:10. 1007/s12015-009-9078-9 (2009).
15. Fusco, A., Fedele, M. Roles of HMGA proteins in cancer. Nat Rev Cancer 7, 899-910 (2007).
16. Dangi-Garimella, S., Sahai, V., Ebine, K., Kumar, K., Munshi, H. G. Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression. PLoS One 8, e64566, doi:10. 1371/journal. pone. 0064566. PONE-D-13-04642 (2013).
17. Dangi-Garimella, S. et al. Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP-Mediated Expression of HMGA2. Cancer Res 71, 1019-1028, doi:0008-5472. CAN-10-1855 (2011).
18. Holohan, C., Van Schaeybroeck, S., Longley, D. B., Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714-726, doi:10. 1038/nrc3599 (2013).
19. Yang, A. D. et al. Chronic oxaliplatin resistance induces epithelial-tomesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12, 4147-4153, doi:12/14/4147 (2006).
20. Thomson, S. et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65, 9455-9462, doi:10. 1158/0008-5472. CAN-05-1058 (2005).
21. Krantz, S. B., Shields, M. A., Dangi-Garimella, S., Munshi, H. G., Bentrem, D. J. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res 173, 105-112, doi:S0022-4804(11)00749-9 (2012).
22. Thiery, J. P., Acloque, H., Huang, R. Y., Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890, doi:S0092-8674(09)01419-6 (2009).
23. Olson, P. et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 23, 2152-2165, doi:23/18/2152 (2009).
24. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5, 662-668 (1999).
25. Thayer, S. P. et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856, doi:10. 1038/nature02009 (2003).
26. Morton, J. P. et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 104, 5103-5108, doi:10. 1073/pnas. 0701158104 (2007).
27. Kim, Y. et al. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 67, 3583-3593, doi:10. 1158/0008-5472. CAN-06-3040 (2007).
28. Dennler, S., Andre, J., Verrecchia, F., Mauviel, A. Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation. J Biol Chem 284, 31523-31531, doi:10. 1074/jbc. M109. 059964 (2009).
29. Tang, Y. et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 20, 732-740, doi:10. 1038/nm. 3613 (2014).
30. Jones, P. A., Baylin, S. B. The epigenomics of cancer. Cell 128, 683-692, doi:10. 1016/j. cell. 2007. 01. 029 (2007).
31. Dawson, M. A., Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27, doi:10. 1016/j. cell. 2012. 06. 013 (2012).
32. Popovic, R., Licht, J. D. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2, 405-413, doi:2159-8290. CD-12-0076 (2012).
33. Shi, J., Vakoc, C. R. The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition. Mol Cell 54, 728-736, doi:10. 1016/j. molcel. 2014. 05. 016 (2014).
34. Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282, doi:10. 1038/nature13229 (2014).
35. Chaidos, A. et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 123, 697-705, doi:10. 1182/blood-2013-01-478420 (2014).
36. De Raedt, T. et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514, 247-251, doi:10. 1038/nature13561 (2014).
37. Feng, Q. et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell research 24, 809-819, doi:10. 1038/cr. 2014. 71 (2014).
38. Fiskus, W. et al. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther 13, 2315-2327, doi:10. 1158/1535-7163. MCT-14-0258 (2014).
39. Steg, A. D. et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18, 869-881, doi:10. 1158/1078-0432. CCR-11-2188 (2012).
40. Kudo, K. et al. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene 31, 4718-4724, doi:10. 1038/onc. 2011. 610 (2012).
41. Steg, A. D. et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther 11, 1587-1597, doi:10. 1158/1535-7163. MCT-11-1058 (2012).
42. Regl, G. et al. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res 64, 7724-7731, doi:10. 1158/0008-5472. CAN-04-1085 (2004).
43. Narita, S. et al. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res 14, 5769-5777, doi:10. 1158/1078-0432. CCR-07-4282 (2008).
44. Kump, E., Ji, J., Wernli, M., Hausermann, P., Erb, P. Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis. Oncogene 27, 3856-3864, doi:10. 1038/onc. 2008. 5 (2008).
45. Wang, Z. et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Research 69, 2400-2407, doi:0008-5472. CAN-08-4312 (2009).
46. Shah, A. N. et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Annals of Surgical Oncology 14, 3629-3637, doi:10. 1245/s10434-007-9583-5 (2007).
47. Arumugam, T. et al. Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. Cancer Research 69, 5820-5828, doi:10. 1158/0008-5472. CAN-08-2819 (2009).
48. Buck, E. et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6, 532-541, doi:10. 1158/1535-7163. MCT-06-0462 (2007).
49. Aoudjit, F., Vuori, K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20, 4995-5004, doi:10. 1038/sj. onc. 1204554 (2001).
50. Yang, X. H. et al. Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70, 2256-2263, doi:10. 1158/0008-5472. CAN-09-4032 (2010).
51. Kanda, R. et al. Erlotinib resistance in lung cancer cells mediated by integrin beta1/Src/Akt-driven bypass signaling. Cancer Res 73, 6243-6253, doi:10. 1158/0008-5472. CAN-12-4502 (2013).
52. Huanwen, W. et al. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 8, 125, doi:10. 1186/1476-4598-8-125 (2009).
53. Shields, M. A., Dangi-Garimella, S., Krantz, S. B., Bentrem, D. J., Munshi, H. G. Pancreatic Cancer Cells Respond to Type I Collagen by Inducing Snail Expression to Promote Membrane Type 1 Matrix Metalloproteinase-dependent Collagen Invasion. J Biol Chem 286, 10495-10504, doi:M110. 195628 (2011).
54. Shields, M. A., Krantz, S. B., Bentrem, D. J., Dangi-Garimella, S., Munshi, H. G. Interplay between beta1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem 287, 6218-6229, doi:M111. 308940 (2012).
55. Dangi-Garimella, S., Redig, A. J., Shields, M. A., Siddiqui, M. A., Munshi, H. G. Rho-ROCK-myosin signaling mediates membrane type 1 matrix metalloproteinase-induced cellular aggregation of keratinocytes. J Biol Chem 285, 28363-28372, doi:M110. 146019 (2010).
56. Lin, L., Zhang, J. H., Panicker, L. M., Simonds, W. F. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc protooncogene. Proc Natl Acad Sci USA 105, 17420-17425, doi:0710725105 (2008).